Natco Pharma enters agreement with Eli Lilly for COVID drug Baricitinib

Published On 2021-05-18 06:21 GMT   |   Update On 2021-05-18 06:21 GMT
Advertisement

Hyderabad: Drugmaker, Natco Pharma Limited, has recently announced the signing of a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company, for the manufacture and commercialization of the drug Baricitinib for Covid-19 indication in India.

In line with the licensing agreement, Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India.

Advertisement

NATCO had earlier received an emergency use authorization for Baricitinib tablets, from Central Drugs Standard Control Organization (CDSCO), for use in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Read also: Natco Pharma launches Baricitinib in India without patent waiver approval

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.

The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.





Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News